Stem Cell

Stem Cell and Preclinical Drug Discovery: New Products and Services

We have ventured into preclinical drug discovery space using unique technology of induced pluripotent stem cells (iPSCs) that received a Nobel Prize in Medicine in 2012. This technology opened up a plethora of possibilities for clinical discovery in the oncology space. Our core research objectives in the stem cell program are:

      • Bio-banking of human clinical samples.
      • Use of iPSCs and its derivatives for Drug Discovery and Disease Modeling.
      • Use of iPSC Derived Differentiated Lineages such as Cardiomyocytes and Hepatocytes for Drug Toxicology.
      • Regenerative Medicine and Therapy.

     

Major Accomplishments

Our stem cell program has developed various primary cancer cell and stem cell derived platforms from human subjects (healthy volunteers and/or patients with cancer originating in different tissues), for use in preclinical drug discovery, screening and toxicology.

Flagship Products For Preclinical Cancer Research

“Well characterized” products being developed and likely to be made commercially available soon are:

  • Primary human cancer epithelial cells (e.g. from patients with Breast Cancer, Ovarian Cancer, Prostate Cancer etc.) useful for preclinical drug (efficacy testing) discovery research.
  • Primary human PBMCs (Peripheral Blood Mononuclear Cells) for research and development.
  • Human induced pluripotent stem cells from healthy subjects, breast cancer patients, ovarian cancer patients etc. for clinical discovery.
  • Human iPSC derived Cardiomyocytes (Beating cardiomyocytes, showing positive expression of Troponin T, Nkx2-5 etc.) useful for preclinical drug screening and toxicology.
  • Human iPSC derived Hepatocytes (showing positive albumin expression and secretion, LDL uptake, Glycogen storage etc.) useful for preclinical drug screening and toxicology.
  • Human adipose derived Mesenchymal Stem Cells (MSCs) showing >99% expression of CD90, CD105, CD73 etc., useful for research and development.

Customised Services For Drug Screening & Toxicology

“Well streamlined” services developed and likely to be made commercially available soon are:

  • Bio-banking and collection of human bio-specimens for various disease indications such as cancer.
  • Customized development of primary human cancer epithelial cells collected from patients with Breast Cancer, Ovarian Cancer, and Prostate Cancer.
  • Oncology Drug Screening Services: Use of a panel of primary cancer epithelial cells and established immortalized cancer cell lines for customized drug screening and efficacy testing including dose and time response studies using novel drug candidates and their combinations.
  • Customized development of primary human PBMCs (Peripheral Blood Mononuclear Cells) or other cell populations derived from human blood.
  • Customized development of human iPSC from healthy subjects and patients with specified disease indications.
  • Customized development of human iPSC derived cardiomyocytes (Beating cardiomyocytes, showing positive expression of Troponin T, Nkx2-5 etc.) useful for preclinical drug screening and toxicology.
  • Customized development of human iPSC derived hepatocytes (showing positive albumin expression and secretion, LDL uptake etc.) useful for preclinical drug screening and toxicology.
  • High-throughput Drug Toxicology Services: Use of iPSC derived cardiomyocytes and/or hepatocytes for customized drug screening and toxicology portfolio development including cell viability, cell proliferation, cell migration, mitotic indices, cell apoptosis, molecular gene and protein profiling, cell signaling and electrophysiological analyses in response to dose and time response studies using novel drug candidates.
  • Customized development of human adipose derived Mesenchymal Stem Cells (MSCs) showing >99% expression of CD90, CD105, CD73 etc., their differentiation into desired lineages useful for research and development.